Amgen, Novartis Are Investors In Atlas Venture’s Ninth Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Atlas pledges to explore areas of mutual interest to the firm and its new corporate limited partners, but the drug firms won’t receive exclusive rights to anything in the new fund’s portfolio.